Syros Pharmaceuticals Inc (SYRS)
5.18
+0.19
(+3.81%)
USD |
NASDAQ |
Apr 23, 11:30
Syros Pharmaceuticals Debt to Equity Ratio: 2.474 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.474 |
| September 30, 2023 | 1.131 |
| June 30, 2023 | 0.5589 |
| March 31, 2023 | 0.382 |
| December 31, 2022 | 0.3182 |
| September 30, 2022 | 0.3136 |
| June 30, 2022 | 1.31 |
| March 31, 2022 | 0.6446 |
| December 31, 2021 | 0.4724 |
| September 30, 2021 | 0.3778 |
| June 30, 2021 | 0.3069 |
| March 31, 2021 | 0.265 |
| December 31, 2020 | 0.4368 |
| September 30, 2020 | 0.4292 |
| June 30, 2020 | 0.3147 |
| March 31, 2020 | 0.2556 |
| December 31, 2019 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Jun 2019
2.474
Maximum
Dec 2023
0.5259
Average
0.3778
Median
Sep 2021
Debt to Equity Ratio Benchmarks
| PDS Biotechnology Corp | -- |
| PAVmed Inc | -0.8211 |
| Moderna Inc | 0.00 |
| Altimmune Inc | 0.00 |
| iBio Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 168.17M |
| Total Liabilities (Quarterly) | 151.51M |
| Shareholders Equity (Quarterly) | 16.66M |
| Current Ratio | 3.952 |
| Net Debt Paydown Yield | -0.07% |